Neoadjuvant Targeted Therapy for Resectable ALK-fusion Locally Advanced Non-small Cell Lung Cancer

Locally advanced non-small cell lung cancer (NSCLC) is a highly heterogeneous entity with multidimensional treatments involved. Neoadjuvant therapy is widely applied for patients with locally advanced NSCLC. Previous studies indicated that epidermal growth factor receptor(EGFR)-tyrosine kinase inhibitor (TKI) therapy may be an optimal strategy for patients with EGFR mutant. But for patients with anaplastic lymphoma kinase (ALK) fusion, whether targeted therapy is a feasible and well tolerated therapy is poorly explored.